Ligand acquires milestone and royalty rights to SB206 from Novan

This article was originally published here

Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20

The post Ligand acquires milestone and royalty rights to SB206 from Novan appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply